0HX7 Stock Chart & Stats
$8.20
-$0.33(-4.02%)
At close: 4:00 PM EDT
$8.20
-$0.33(-4.02%)
Day’s Range― - ―
52-Week Range$6.11 - $22.40
Previous CloseN/A
Volume28.00
Average Volume (3M)226.00
Market Cap
$83.79M
Enterprise Value-$12.49
Total Cash (Recent Filing)$118.19M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 11, 2026EPS Estimate
-1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume304
30 Day Avg. Volume226
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.50Price Target Upside174.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageDebt-to-equity of approximately 0.11 limits balance-sheet leverage and reduces fixed obligations, giving Adicet more flexibility to fund clinical development and absorb setbacks than a similarly loss-making biotech with heavier debt.
Off-the-Shelf Therapy PlatformAn allogeneic, off-the-shelf gamma delta T-cell platform could support more standardized manufacturing and broader treatment availability than individualized cell therapies, creating potential scalability if clinical development demonstrates durable efficacy.
Governance ContinuityThe completed director elections and auditor ratification reinforce continuity in board oversight and financial reporting. Stable governance can help maintain strategic focus and execution discipline during a lengthy clinical development cycle.
Bears Say
No Product RevenueWithout approved commercial products, Adicet lacks recurring operating revenue to fund research and development. Its financial outlook therefore remains dependent on clinical progress, partnerships, and external financing rather than proven customer demand.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that clinical development requires substantial ongoing funding. Continued reliance on external capital may constrain program choices and expose shareholders to dilution or financing risk.
Shrinking Equity BaseThe materially smaller equity base reflects cumulative losses and cash consumption, reducing financial resilience. Despite low debt, continued erosion can limit the company’s ability to sustain multiple programs without additional capital or strategic support.
Adicet Bio News
0HX7 FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest share price was $6.11 and its highest was $22.40 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $83.79M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on Aug 05, 2026. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$1.692 by -$0.298.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -1.59.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,361,490 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.99 in its last earnings report, missing expectations of -$1.692. Following the earnings report the stock price went down -11.868%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in GB:0HX7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (174.39% Upside)
$22.50 (174.39% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
0HX7 Stock 12 Month Forecast
Average Price Target
$22.50
▲(174.39% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―